Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

AstraZeneca : Merck Get CHMP Positive Opinions for Expanded Lynparza Use

share with twitter share with LinkedIn share with facebook
09/21/2020 | 10:28am EDT

By Colin Kellaher

 

AstraZeneca PLC and Merck & Co. Monday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of two additional indications for the cancer drug Lynparza.

The drugmakers said one recommendation covers Lynparza as monotherapy for the treatment of adults with metastatic castration-resistant prostate cancer and BRCA1/2 mutations who have progressed following a prior therapy that included a new hormonal agent.

The second recommendation covers Lynparza as a first-line maintenance treatment in combination with bevacizumab for HRD-positive advanced ovarian cancer.

The indications now await approval from the European Commission, which generally follows the CHMP's recommendations.

AstraZeneca and Merck in 2017 formed a collaboration to co-develop and co-commercialize Lynparza for multiple cancer types.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 


Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -0.15% 7943 Delayed Quote.4.42%
MERCK & CO., INC. 0.78% 79.83 Delayed Quote.-12.23%
share with twitter share with LinkedIn share with facebook
All news about ASTRAZENECA PLC
05:17pAstraZeneca resumes U.S. COVID-19 vaccine trial and next week J&J prepares to..
RE
12:16aTo Find a Coronavirus Vaccine, GlaxoSmithKline Is Bonding With Its Biggest Co..
DJ
10/23ASTRAZENECA : says its Oxford vaccine deal allows it to add up to 20% of manufac..
RE
10/23NEWS HIGHLIGHTS : Top Company News of the Day
DJ
10/23NEWS HIGHLIGHTS : Top Company News of the Day
DJ
10/23Health Care Up After Final Presidential Debate -- Health Care Roundup
DJ
10/23ASTRAZENECA : Covid-19 Vaccine Trial From AstraZeneca, Oxford Can Resume in U.S...
DJ
10/23ASTRAZENECA : Pivotal Studies of Covid-19 Vaccines From AstraZeneca, J&J Resumin..
DJ
10/23ASTRAZENECA : Says FDA Authorises Restart Of COVID-19 Vaccine Trial in U.S.
RE
10/23NEWS HIGHLIGHTS : Top Company News of the Day
DJ
More news
Financials (USD)
Sales 2020 26 703 M - -
Net income 2020 3 074 M - -
Net Debt 2020 13 178 M - -
P/E ratio 2020 47,1x
Yield 2020 2,72%
Capitalization 136 B 136 B -
EV / Sales 2020 5,58x
EV / Sales 2021 4,86x
Nbr of Employees 70 600
Free-Float 95,7%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 118,27 $
Last Close Price 103,58 $
Spread / Highest target 50,1%
Spread / Average Target 14,2%
Spread / Lowest Target -36,3%
EPS Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC4.42%135 994
JOHNSON & JOHNSON-0.43%382 391
ROCHE HOLDING AG-5.29%280 884
PFIZER INC.-2.55%212 162
MERCK & CO., INC.-12.23%201 909
NOVARTIS AG-16.78%185 999